CVS's stock jumps, as profit beats by a wide margin and the outlook is raised

Dow Jones

2025/07/31

MW CVS's stock jumps, as profit beats by a wide margin and the outlook is raised

Shares of CVS Health Corp. $(CVS.AU)$ shot up 8.9% in premarket trading Thursday, after the health and pharmacy services company beat profit second-quarter expectations by a wide margin and raised its full-year outlook, amid strength in its prescription pharmacy business.

Net income fell 42.3% from the same period a year ago to $1.02 billion, due in part to one-time litigation charges, while adjusted earnings per share, which excludes special items, fell to $1.81 from $1.83 but beat the average analyst estimate compiled by FactSet of $1.46.

For 2025, the company raised its adjusted EPS guidance range to $6.30 to $6.40 from $6.00 to $6.20. The FactSet consensus for 2025 adjusted EPS is $6.12.

Total revenue grew 8.4% to $98.92 billion, above the FactSet consensus of $94.51 billion.

Among CVS's business units - there is some revenue overlap between the units - pharmacy and consumer wellness revenue increased 12.5% to $33.58 billion, boosted by increased prescription and front-store volume, while health care benefits rvenue rose 11.6% to $36.26 billion.

Revenue for health services, which includes the company's CVS Caremark pharmacy benefit manager business, was up 10.2% to $46.45 billion.

-Tomi Kilgore

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

July 31, 2025 06:55 ET (10:55 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2555881768"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555881768\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555881768?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-31 18:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555881768","market":"fut","top_or_hot":-1,"title":"CVS's stock jumps, as profit beats by a wide margin and the outlook is raised","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW CVS's stock jumps, as profit beats by a wide margin and the outlook is raised\n</p>\n<p>\n     Shares of <a href=\"https://laohu8.com/S/CVS\">CVS Health</a> Corp. <a href=\"https://laohu8.com/S/CVS.AU\">$(CVS.AU)$</a> shot up 8.9% in premarket trading Thursday, after the health and pharmacy services company beat profit second-quarter expectations by a wide margin and raised its full-year outlook, amid strength in its prescription pharmacy business. \n</p>\n<p>\n     Net income fell 42.3% from the same period a year ago to $1.02 billion, due in part to one-time litigation charges, while adjusted earnings per share, which excludes special items, fell to $1.81 from $1.83 but beat the average analyst estimate compiled by FactSet of $1.46. \n</p>\n<p>\n     For 2025, the company raised its adjusted EPS guidance range to $6.30 to $6.40 from $6.00 to $6.20. The FactSet consensus for 2025 adjusted EPS is $6.12. \n</p>\n<p>\n     <a href=\"https://laohu8.com/S/TSS\">Total</a> revenue grew 8.4% to $98.92 billion, above the FactSet consensus of $94.51 billion. \n</p>\n<p>\n     Among CVS's business units - there is some revenue overlap between the units - pharmacy and consumer wellness revenue increased 12.5% to $33.58 billion, boosted by increased prescription and front-store volume, while health care benefits rvenue rose 11.6% to $36.26 billion. \n</p>\n<p>\n     Revenue for health services, which includes the company's CVS Caremark pharmacy benefit manager business, was up 10.2% to $46.45 billion. \n</p>\n<p>\n     -Tomi Kilgore \n</p>\n<p>\n     This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 31, 2025 06:55 ET (10:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CVS's stock jumps, as profit beats by a wide margin and the outlook is raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCVS's stock jumps, as profit beats by a wide margin and the outlook is raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-31 18:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW CVS's stock jumps, as profit beats by a wide margin and the outlook is raised\n</p>\n<p>\n     Shares of <a href=\"https://laohu8.com/S/CVS\">CVS Health</a> Corp. <a href=\"https://laohu8.com/S/CVS.AU\">$(CVS.AU)$</a> shot up 8.9% in premarket trading Thursday, after the health and pharmacy services company beat profit second-quarter expectations by a wide margin and raised its full-year outlook, amid strength in its prescription pharmacy business. \n</p>\n<p>\n     Net income fell 42.3% from the same period a year ago to $1.02 billion, due in part to one-time litigation charges, while adjusted earnings per share, which excludes special items, fell to $1.81 from $1.83 but beat the average analyst estimate compiled by FactSet of $1.46. \n</p>\n<p>\n     For 2025, the company raised its adjusted EPS guidance range to $6.30 to $6.40 from $6.00 to $6.20. The FactSet consensus for 2025 adjusted EPS is $6.12. \n</p>\n<p>\n     <a href=\"https://laohu8.com/S/TSS\">Total</a> revenue grew 8.4% to $98.92 billion, above the FactSet consensus of $94.51 billion. \n</p>\n<p>\n     Among CVS's business units - there is some revenue overlap between the units - pharmacy and consumer wellness revenue increased 12.5% to $33.58 billion, boosted by increased prescription and front-store volume, while health care benefits rvenue rose 11.6% to $36.26 billion. \n</p>\n<p>\n     Revenue for health services, which includes the company's CVS Caremark pharmacy benefit manager business, was up 10.2% to $46.45 billion. \n</p>\n<p>\n     -Tomi Kilgore \n</p>\n<p>\n     This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 31, 2025 06:55 ET (10:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1571399168.USD","symbol_name":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2555881768","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555881768","pubTimestamp":1753959300,"columns":[{"name":"行业数据","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of CVS Health Corp.  shot up 8.9% in premarket trading Thursday, after the health and pharmacy services company beat profit second-quarter expectations by a wide margin and raised its full-year outlook, amid strength in its prescription pharmacy business.Net income fell 42.3% from the same period a year ago to $1.02 billion, due in part to one-time litigation charges, while adjusted earnings per share, which excludes special items, fell to $1.81 from $1.83 but beat the average analyst estimate compiled by FactSet of $1.46.For 2025, the company raised its adjusted EPS guidance range to $6.30 to $6.40 from $6.00 to $6.20. The FactSet consensus for 2025 adjusted EPS is $6.12.Total revenue grew 8.4% to $98.92 billion, above the FactSet consensus of $94.51 billion.Among CVS's business units - there is some revenue overlap between the units - pharmacy and consumer wellness revenue increased 12.5% to $33.58 billion, boosted by increased prescription and front-store volume, while health","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","BK4581":"高盛持仓","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","BK4504":"桥水持仓","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4588":"碎股","BK4550":"红杉资本持仓","BK4585":"ETF&股票定投概念","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK4196":"保健护理服务","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","CVS":"西维斯健康","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD"},"translate_title":"CVS股价上涨，利润超过预期大幅上涨且前景上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CVS":1},"content_text":"MW CVS's stock jumps, as profit beats by a wide margin and the outlook is raised\n\n\n     Shares of CVS Health Corp. $(CVS.AU)$ shot up 8.9% in premarket trading Thursday, after the health and pharmacy services company beat profit second-quarter expectations by a wide margin and raised its full-year outlook, amid strength in its prescription pharmacy business. \n\n\n     Net income fell 42.3% from the same period a year ago to $1.02 billion, due in part to one-time litigation charges, while adjusted earnings per share, which excludes special items, fell to $1.81 from $1.83 but beat the average analyst estimate compiled by FactSet of $1.46. \n\n\n     For 2025, the company raised its adjusted EPS guidance range to $6.30 to $6.40 from $6.00 to $6.20. The FactSet consensus for 2025 adjusted EPS is $6.12. \n\n\nTotal revenue grew 8.4% to $98.92 billion, above the FactSet consensus of $94.51 billion. \n\n\n     Among CVS's business units - there is some revenue overlap between the units - pharmacy and consumer wellness revenue increased 12.5% to $33.58 billion, boosted by increased prescription and front-store volume, while health care benefits rvenue rose 11.6% to $36.26 billion. \n\n\n     Revenue for health services, which includes the company's CVS Caremark pharmacy benefit manager business, was up 10.2% to $46.45 billion. \n\n\n     -Tomi Kilgore \n\n\n     This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 31, 2025 06:55 ET (10:55 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}